ClinicalTrials.gg
CompletedNCT00365365Updated Sep 14, 2012Results posted

Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer

A Phase 2 interventional study of Doxorubicin and cyclophosphamide (AC) + bevacizumab and Docetaxel (T) + bevacizumab in Breast Cancer, sponsored by Sanofi. Completed at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-09-14.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
214
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 197 studies testing doxorubicin in Breast Neoplasms — 9 open to participants now, 18 under way, 5 of them phase 3. Doxorubicin · Breast Neoplasms.

Enrollment
33rd of 189
214 · median 56
Started
2006
with 18 others
Phase 2
110 of 197
3 open now
Registered
72nd of 197
by date

Among the 197 studies testing doxorubicin in Breast Neoplasms, this one is the 33rd largest by enrollment of the 189 interventional ones that give a count, is one of 19 that started in 2006, is one of 110 in phase 2, and was the 72nd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

9 of the 197 studies testing doxorubicin in Breast Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About doxorubicin

Doxorubicin: first FDA approval 1974 (DOXORUBICIN HYDROCHLORIDE), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 197 studies testing doxorubicin in Breast Neoplasms, or all of them as a file.
02

Study summary

This is a phase IIb, randomized, parallel-group, noncomparative, multicenter, pilot study designed to evaluate the safety and efficacy of bevacizumab with or without (+/-) trastuzumab administered with three different docetaxel-based combination regimens for the adjuvant treatment of participants with node positive or high-risk node negative breast cancer.

Read the detailed description

In this study, participants were stratified according to HER2 status at the time of enrollment. HER2-negative participants were randomized in a 1:1 ratio to either stratum 1 (AC->T sequential + bevacizumab) or stratum 2 (TAC + bevacizumab). All HER2-positive participants were assigned to stratum 3 (TCH + bevacizumab).

The study included a treatment period of 1 year, followed by a 2 year posttreatment survival follow-up period.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

The following information on clinical trials is provided for information purposes only to allow participants and physicians to have an initial discussion about the trial. This information is not intended to be complete information about the trial, to contain all considerations that may be relevant to potential participation in the trial, or to replace the advice of a personal physician or health professional.

Inclusion criteria

Inclusion Criteria:

  • Women >/= 18 years of age.
  • proven breast cancer with an interval between definitive breast surgery that includes axillary lymph node (LN) dissection or axillary nodal evaluation and study registration of \< 60 days. (Note: Cycle 1 of chemotherapy treatment may NOT be infused until > 28 days after the date of definitive breast surgery and the participant must be recovered from any toxicity thereof.)
  • Definitive surgical treatment must be either mastectomy, or breast conserving surgery with axillary lymph node dissection (axillary lymph node evaluation can be either full axillary node dissection or sentinel LN evaluation followed by dissection if sentinel LN is positive) for operable breast cancer (pT1-4 [including inflammatory], pNO-3, and MO). Margins of resected specimen from definitive surgery must be histologically free of invasive adenocarcinoma and ductal carcinoma in-situ (DCIS). Lobular carcinoma in-situ does not count as a positive margin.
  • Subjects must be either lymph node-positive (pN1-3) or lymph node-negative (pN0) with high-risk features as determined by Investigator.
  • High-risk, lymph node-negative participants, (pN0) will be defined as subjects having invasive adenocarcinoma with either a negative sentinel node (pN0[sn]) OR negative lymph node dissection (pN0) disease AND tumor size > 2 cm or tumor size >/= 1 cm with at least one of the following factors:

    • negative estrogen receptor (ER) and negative progesterone receptor (PR) status
    • histologic and/or nuclear Grade 2-3; or
    • age \< 35 years
  • /neu positive or negative tumors are eligible. HER2 positivity must be documented by fluorescence in situ hybridization (FISH).
  • Estrogen and progesterone receptor status must be performed on the primary tumor prior to study entry. Results must be pending or known at the time of study entry.
  • Normal cardiac function must be confirmed by (LVEF) or shortening fraction (multiple-gated acquisition [MUGA] scan or echocardiography respectively). The result must be greater than the lower limit of normal (LLN) for the institution.
  • Hematology evaluation within 2 weeks prior to study entry:

    • (ANC) >/= 1,500/μL
    • >/= 100,000/μL
    • >/= 9 g/dL
  • Hepatic function evaluation within 2 weeks prior to study entry:

    • Total \</= for the institution
    • (AST) and alanine aminotransferase (ALT) must be in the acceptable range.
  • Complete staging work-up as follows: All subjects must have an appropriate radiographic evaluation, e.g., computed tomography (CT), positron emission tomography (PET)/CT, and/or (magnetic resonance imaging) MRI of the brain, chest, abdomen and pelvis, and imaging of bone by either a bone scan or PET scan. In cases of positive bone imaging, a bone X-ray or MRI evaluation is mandatory to rule out the possibility of bone scan disease. Other tests may be performed as clinically indicated. It is recommended that all baseline staging should be completed within 35 days prior to study entry.

Exclusion criteria

Exclusion Criteria:

  • Prior systemic anticancer therapy for breast cancer (immunotherapy, hormonotherapy, chemotherapy).
  • Prior anthracycline therapy, taxoids or platinum salts for any .
  • Prior radiation therapy for breast cancer or any radiotherapy to the chest wall for any other malignancy.
  • Bilateral invasive breast cancer.
  • Pregnant or lactating subjects
  • Cardiac disease or risk for same as judged by Investigator
  • Other serious illness or medical conditions such as (partial list- review with Investigator) history of significant neurologic or psychiatric disorders that would prohibit the understanding and giving of , active uncontrolled infection, active peptic ulcer, unstable diabetes mellitus or subjects with symptomatic, intrinsic lung disease resulting in dyspnea at rest
  • Current therapy with any hormonal agent such as raloxifene, tamoxifen, or other selective estrogen receptor modulators (SERMs), either for osteoporosis or prevention of breast cancer. Subjects must have discontinued these agents prior to study entry.
  • Concurrent treatment with ovarian hormonal replacement therapy. Prior treatment must be stopped prior to study entry.
  • Concurrent treatment with other experimental drugs. Participation in another clinical trial with any non-marketed drug within 30 days prior to study entry.
  • Concurrent treatment with any other anti-cancer therapy.
  • Male subjects, as no clinical efficacy or safety data are available from phase I-II studies.
  • Chemotherapy and/or bevacizumab may not be given until > 7 days following a minor surgical procedure. Chemotherapy may be given without bevacizumab in circumstances in which the participant has recovered sufficiently to receive chemotherapy but has not yet reached a 28 day time point at which bevacizumab could be administered.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
214 participants (actual)

Study arms

  • Experimental
    Stratum 1 (AC->T + bevacizumab)

    HER2-negative participants administered * doxorubicin and cyclophosphamide (AC) + bevacizumab for 4 cycles followed by * docetaxel (T) + bevacizumab for 4 cycles followed by * bevacizumab maintenance therapy for total of 52 weeks from date of first dose regardless of number of doses received or missed

    Drug: Doxorubicin and cyclophosphamide (AC) + bevacizumab · Drug: Docetaxel (T) + bevacizumab · Drug: Bevacizumab maintenance therapy

  • Experimental
    Stratum 2 (TAC + bevacizumab)

    HER2-negative participants administered * docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab for 6 cycles followed by * bevacizumab maintenance therapy for total of 52 weeks from date of first dose regardless of number of doses received or missed

    Drug: Docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab · Drug: Bevacizumab maintenance therapy

  • Experimental
    Stratum 3 (TCH + bevacizumab)

    All HER2-positive participants administered * docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab for 6 cycles followed by * bevacizumab and trastuzumab maintenance therapy for total of 52 weeks from date of first dose regardless of number of doses received or missed

    Drug: Docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab · Drug: Bevacizumab and trastuzumab maintenance therapy

Interventions

  • DrugDoxorubicin and cyclophosphamide (AC) + bevacizumab

    Drug pages: Doxorubicin · Cyclophosphamide · Bevacizumab

    For every 3-week cycle * bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by * doxorubicin 60 mg/m\^2 IV push or infusion followed by cyclophosphamide 600 mg/m\^2 IV push or infusion * Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy

    Also known as: Avastin® (bevacizumab), Adriamycin® (doxorubicin)

  • DrugDocetaxel (T) + bevacizumab

    Drug pages: Docetaxel · Bevacizumab

    For every 3-week cycle * bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by * docetaxel 100 mg/m\^2 IV * Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy Note: The starting dose of docetaxel was reduced to 75 mg/m\^2 if toxicity occurred that met the criteria for doxorubicin dose reduction

    Also known as: Taxotere® (docetaxel), Avastin® (bevacizumab)

  • DrugDocetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab

    Drug pages: Docetaxel · Doxorubicin · Cyclophosphamide · Bevacizumab

    For every 3-week cycle * bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by * doxorubicin 50 mg/m\^2 IV push or infusion followed by cyclophosphamide 500 mg/m\^2 IV push or infusion followed by docetaxel 75 mg/m\^2 * Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy

    Also known as: Taxotere® (docetaxel), Avastin® (bevacizumab)

  • DrugDocetaxel, carboplatin, trastuzumab (TCH) + bevacizumab

    Drug pages: Docetaxel · Carboplatin · Trastuzumab · Bevacizumab

    For every 3-week cycle * bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by * docetaxel in 75 mg/m\^2 IV followed by carboplatin AUC 6 mg/mL/min IV followed by * trastuzumab 6 mg/kg by IV infusion (For the first cycle 1 only a loading dose of trastuzumab 8 mg/kg IV was infused on Day 2) * Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy

    Also known as: Taxotere® (docetaxel), Herceptin® (trastuzumab), Avastin® (bevacizumab)

  • DrugBevacizumab and trastuzumab maintenance therapy

    Drug pages: Bevacizumab · Trastuzumab

    * bevacizumab 15 mg/kg was infused IV followed by * trastuzumab 6 mg/kg IV Treatment was every 3 weeks for 52 weeks from the date of the first administration regardless of the number of doses received or missed.

    Also known as: Avastin® (bevacizumab), Herceptin® (trastuzumab)

  • - bevacizumab 15 mg/kg was infused IV Treatment was every 3 weeks for 52 weeks from the date of the first administration regardless of the number of doses received or missed.

    Also known as: Avastin® (bevacizumab)

06

What researchers measure

Primary outcomes

  1. Cardiac Safety - Number of Participants With Grade 3-4 Clinical Congestive Heart Failure (CHF)

    Participants were evaluated for clinical CHF every 3 weeks during chemotherapy, every 3 months while on maintenance therapy, and every 3 months during the 2-year follow-up period. Left ventricular ejection fraction (LVEF) of CHF was assessed by multi-gated acquisition (MUGA) or echocardiogram (ECHO) performed midway through completion of chemotherapy according to a treatment-specific schedule, every 12 weeks during maintenance therapy, and at 6 and 24 months after completion of maintenance therapy. Grade 3-4 CHF were identified through a clinical review of all study collected investigator verbatim and the Medical Dictionary for Regulatory Activities (MedDRA). The preferred terms (PT) cardiac failure congestive, cardiomyopathy, and ejection fraction decreased were associated with CHF.

    Time frame: from the first dose of study medication up to the end of follow-up (up to 3 yrs)

Secondary outcomes

  1. Safety - Number of Participants With Adverse Events (AE)

    An adverse event was any untoward medical occurrence in a participant of the clinical investigation, regardless of the relationship to study treatment. A serious adverse event (SAE) was an AE that at any dose (including overdose) resulted in death, was life-threatening, required inpatient hospitalization or prolonged existing hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly/birth defect, and/or was medically important. Treatment-emergent adverse events (TEAE) were defined as AEs that developed or worsened in severity during the on-treatment period.

    Time frame: from the administration of the first dose of study medication up to 30 days after the last dose of study medication; events ongoing at the time of discontinuation were monitored in the follow-up period until resolution.

  2. Disease-free Survival (DFS) Rate

    DFS was defined as the time from the administration of the first-dose of study medication until recurrence of tumor or death from any cause in the absence of previous documentation of tumor recurrence. DFS rate was the probability of being disease free and alive at a particular time. DFS rates were estimated using Kaplan-Meier Method, and 95% confidence intervals were computed using the method of Kalbfleisch and Prentice. For participants who did have objective recurrence of tumor and who were still on study at the time of an analysis, or who were given antitumor treatment other than the study treatment, or who were removed from study follow-up prior to documentation of the tumor recurrence, DFS was censored at the last date the participant was known to be disease-free.

    Time frame: from the administration of the first-dose of study medication up to 12 months, 18 months and 24 months

07

Results

Posted Sep 14, 2012
Limitations and caveats
The study was originally designed to last for 6-10 years. Based on a protocol amendment, the study was shortened to about 3 years, and the endpoint Overall Survival (OS) was deleted.

Participant flow

239 participants were screened in this study. 214 were considered eligible for enrollment and 25 were screen failures. Of the 214 eligible participants, 155 were HER2-negative and 59 were HER2-positive.

Participant flow — Overall Study
MilestoneStratum 1 (AC->T + Bevacizumab)Stratum 2 (TAC + Bevacizumab)Stratum 3 (TCH + Bevacizumab).)
Started787759
Treated (safety population)787559
Completed treatment383645
Completed444144
Not completed343615
Withdrew: Randomized but not treated020
Withdrew: Poor compliance to protocol010
Withdrew: Lost to follow-up333
Withdrew: Death130
Withdrew: Subject's request11131
Withdrew: Disease progression/relapse967
Withdrew: Adverse event663
Withdrew: Moved200
Withdrew: New cancer100
Withdrew: Withdrew consent110
Withdrew: Second malignancy010
Withdrew: Patient/physician decision001

Outcome measures

PrimaryCardiac Safety - Number of Participants With Grade 3-4 Clinical Congestive Heart Failure (CHF)

Participants were evaluated for clinical CHF every 3 weeks during chemotherapy, every 3 months while on maintenance therapy, and every 3 months during the 2-year follow-up period. Left ventricular ejection fraction (LVEF) of CHF was assessed by multi-gated acquisition (MUGA) or echocardiogram (ECHO) performed midway through completion of chemotherapy according to a treatment-specific schedule, every 12 weeks during maintenance therapy, and at 6 and 24 months after completion of maintenance therapy. Grade 3-4 CHF were identified through a clinical review of all study collected investigator verbatim and the Medical Dictionary for Regulatory Activities (MedDRA). The preferred terms (PT) cardiac failure congestive, cardiomyopathy, and ejection fraction decreased were associated with CHF.

Time frame:
from the first dose of study medication up to the end of follow-up (up to 3 yrs)
Reported as:
Number · participants
Cardiac Safety - Number of Participants With Grade 3-4 Clinical Congestive Heart Failure (CHF)
participantsStratum 1 (AC->T + Bevacizumab)Stratum 2 (TAC + Bevacizumab)Stratum 3 (TCH + Bevacizumab).)
Cardiac Safety - Number of Participants With Grade 3-4 Clinical Congestive Heart Failure (CHF)1 (0.0 to 6.9)3 (0.8 to 11.2)1 (0.0 to 0.1)
SecondarySafety - Number of Participants With Adverse Events (AE)

An adverse event was any untoward medical occurrence in a participant of the clinical investigation, regardless of the relationship to study treatment. A serious adverse event (SAE) was an AE that at any dose (including overdose) resulted in death, was life-threatening, required inpatient hospitalization or prolonged existing hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly/birth defect, and/or was medically important. Treatment-emergent adverse events (TEAE) were defined as AEs that developed or worsened in severity during the on-treatment period.

Time frame:
from the administration of the first dose of study medication up to 30 days after the last dose of study medication; events ongoing at the time of discontinuation were monitored in the follow-up period until resolution.
Reported as:
Number · participants
Safety - Number of Participants With Adverse Events (AE)
participantsStratum 1 (AC->T + Bevacizumab)Stratum 2 (TAC + Bevacizumab)Stratum 3 (TCH + Bevacizumab).)
with TEAE787559
with serious TEAE232412
with any TEAE leading to death020
with any TEAE leading to treatment discontinuation212416
with any Grade 3-4 Serious TEAE23249
SecondaryDisease-free Survival (DFS) Rate

DFS was defined as the time from the administration of the first-dose of study medication until recurrence of tumor or death from any cause in the absence of previous documentation of tumor recurrence. DFS rate was the probability of being disease free and alive at a particular time. DFS rates were estimated using Kaplan-Meier Method, and 95% confidence intervals were computed using the method of Kalbfleisch and Prentice. For participants who did have objective recurrence of tumor and who were still on study at the time of an analysis, or who were given antitumor treatment other than the study treatment, or who were removed from study follow-up prior to documentation of the tumor recurrence, DFS was censored at the last date the participant was known to be disease-free.

Time frame:
from the administration of the first-dose of study medication up to 12 months, 18 months and 24 months
Reported as:
Number · percentage of participants
Disease-free Survival (DFS) Rate
percentage of participantsStratum 1 (AC->T + Bevacizumab)Stratum 2 (TAC + Bevacizumab)Stratum 3 (TCH + Bevacizumab).)
DFS rate at 12 months93.6 (83.8 to 97.5)95.9 (87.8 to 98.7)98.2 (87.8 to 99.7)
DFS rate at 24 months87.1 (75.9 to 93.4)94.1 (84.8 to 97.8)96.3 (86.0 to 99.1)
DFS rate at 36 months85.5 (74.0 to 92.2)90.4 (79.6 to 95.6)90.4 (78.5 to 95.9)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AC->T + Bevacizumab—23/78 (29.5%)78/78 (100%)
TAC + Bevacizumab—24/75 (32%)75/75 (100%)
TCH + Bevacizumab—12/59 (20.3%)59/59 (100%)
Most frequent serious events
Showing 10 of 61
Most frequent serious events
EventAC->T + BevacizumabTAC + BevacizumabTCH + Bevacizumab
Febrile neutropeniaBlood and lymphatic system disorders4/788/750/59
DehydrationMetabolism and nutrition disorders1/784/750/59
NeutropeniaBlood and lymphatic system disorders1/783/750/59
ThrombocytopeniaBlood and lymphatic system disorders0/782/750/59
Cardiac failure congestiveCardiac disorders1/782/750/59
ColitisGastrointestinal disorders0/782/750/59
Deep vein thrombosisVascular disorders2/781/750/59
DiarrhoeaGastrointestinal disorders1/781/751/59
Gastrointestinal haemorrhageGastrointestinal disorders0/780/751/59
Irritable bowel syndromeGastrointestinal disorders0/780/751/59
Most frequent other events
Showing 10 of 127
Most frequent other events
EventAC->T + BevacizumabTAC + BevacizumabTCH + Bevacizumab
FatigueGeneral disorders71/7861/7551/59
NauseaGastrointestinal disorders64/7860/7551/59
AlopeciaSkin and subcutaneous tissue disorders58/7848/7550/59
ArthralgiaMusculoskeletal and connective tissue disorders51/7837/7532/59
DiarrhoeaGastrointestinal disorders39/7848/7538/59
AnaemiaBlood and lymphatic system disorders45/7842/7532/59
NeutropeniaBlood and lymphatic system disorders41/7841/758/59
EpistaxisRespiratory, thoracic and mediastinal disorders36/7832/7532/59
ConstipationGastrointestinal disorders40/7829/7530/59
Decreased appetiteMetabolism and nutrition disorders39/7825/7522/59

Baseline characteristics

Age Continuous
Age Continuous(years)Stratum 1 (AC->T + Bevacizumab)Stratum 2 (TAC + Bevacizumab)Stratum 3 (TCH + Bevacizumab).)Total
Mean53.0 ± 10.4555.1 ± 9.8950.8 ± 9.6153.1 ± 10.12
Sex: Female, Male
Sex: Female, Male(Participants)Stratum 1 (AC->T + Bevacizumab)Stratum 2 (TAC + Bevacizumab)Stratum 3 (TCH + Bevacizumab).)Total
Female787559212
Male0000
Eastern Cooperative Oncology Group Score (ECOG)
Eastern Cooperative Oncology Group Score (ECOG)(participants)Stratum 1 (AC->T + Bevacizumab)Stratum 2 (TAC + Bevacizumab)Stratum 3 (TCH + Bevacizumab).)Total
ECOG Score = 0736755195
ECOG Score = 158417
Electrocardiogram (ECG)
Electrocardiogram (ECG)(participants)Stratum 1 (AC->T + Bevacizumab)Stratum 2 (TAC + Bevacizumab)Stratum 3 (TCH + Bevacizumab).)Total
Normal455336134
Abnormal22191960
Not done/missing113418
08

Study locations

1 site
  • Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2006, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2012, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2006
First posted
Aug 17, 2006
Start
Aug 2006
Primary completionActual
Oct 2011
CompletionActual
Oct 2011
Results first posted
Sep 14, 2012
Last update
Sep 14, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00365365
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Aug 17, 2006
Start date
Aug 2006
Primary completion
Oct 2011
Completion
Oct 2011
Results posted
Sep 14, 2012
Last update
Sep 14, 2012

Study contacts

Vicki Erickson, MSN
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Doxorubicin · Cyclophosphamide · Bevacizumab · Docetaxel · Carboplatin · Trastuzumab

Start the discussion